Lene Schurmann1, Anne Vinkel Hansen2, Ester Garne3. 1. Paediatric Department, Hospital Lillebaelt, Kolding, Denmark. Electronic address: lene@schurmann.net. 2. Department of Public Health, University of Copenhagen, Denmark. 3. Paediatric Department, Hospital Lillebaelt, Kolding, Denmark.
Abstract
AIM: To investigate whether fetal exposure to antithyroid drugs (ATD) and levothyroxine affects gestational age (GA), birth weight, birth length, head circumference and prevalence of congenital anomalies. METHODS: Cohort of all pregnancies from GA 12 weeks recorded in Danish registries from 1995-2010. Exposure was having a prescription for ATD or levothyroxine from 91 days before to 91 days after pregnancy start (n=8318). The reference group was pregnant women without exposure of ATD or levothyroxine (n=969303). A subpopulation was linked to the Danish EUROCAT congenital anomaly register. RESULTS: Overall 0.66% of the pregnant women had a prescription for levothyroxine and 0.19% had a prescription for ATD during the exposure period. There was no difference in proportion of live births compared to non-exposed pregnancies, but infants exposed to ATD were more often born very preterm (1.99% versus 0.94% Odds Ratio 2.04, 95% CI 1.46 - 2.86) and had higher infant mortality (Odds ratio 2.37, 95% CI 1.42 - 3.94). Infants exposed to ATD were more likely to have low birth weight and length for GA (Odds ratios 1.29 (1.12 - 1.50) and 1.40 (1.17 - 1.66). There was no difference in head circumference for the 3 exposure groups. Prevalence of congenital anomalies was the same for exposed and non-exposed pregnancies. CONCLUSION: Fetal exposure to ATD resulted in lower GA, birth weight, length and higher infant mortality. Treatment for hypothyroidism had no significant impact on these variables. There was no difference in prevalence of congenital anomalies.
AIM: To investigate whether fetal exposure to antithyroid drugs (ATD) and levothyroxine affects gestational age (GA), birth weight, birth length, head circumference and prevalence of congenital anomalies. METHODS: Cohort of all pregnancies from GA 12 weeks recorded in Danish registries from 1995-2010. Exposure was having a prescription for ATD or levothyroxine from 91 days before to 91 days after pregnancy start (n=8318). The reference group was pregnant women without exposure of ATD or levothyroxine (n=969303). A subpopulation was linked to the Danish EUROCAT congenital anomaly register. RESULTS: Overall 0.66% of the pregnant women had a prescription for levothyroxine and 0.19% had a prescription for ATD during the exposure period. There was no difference in proportion of live births compared to non-exposed pregnancies, but infants exposed to ATD were more often born very preterm (1.99% versus 0.94% Odds Ratio 2.04, 95% CI 1.46 - 2.86) and had higher infant mortality (Odds ratio 2.37, 95% CI 1.42 - 3.94). Infants exposed to ATD were more likely to have low birth weight and length for GA (Odds ratios 1.29 (1.12 - 1.50) and 1.40 (1.17 - 1.66). There was no difference in head circumference for the 3 exposure groups. Prevalence of congenital anomalies was the same for exposed and non-exposed pregnancies. CONCLUSION: Fetal exposure to ATD resulted in lower GA, birth weight, length and higher infant mortality. Treatment for hypothyroidism had no significant impact on these variables. There was no difference in prevalence of congenital anomalies.